Mar 20
2023
Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT886 for Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinomas
SAN DIEGO, March 20, 2023 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in...
Read More
Mar 6
2023
PHANES THERAPEUTICS entered into a research collaboration with Xyphos Biosciences, Inc., an Astellas Company
SAN DIEGO, March 6, 2023 /PRNewswire/ -- Phanes Therapeutics, Inc., a clinical stage biotech company focused on innovative drug discovery and development...
Read More
Jan 17
2023
Phanes Therapeutics’ anti-claudin 18.2 antibody patent granted in the US
SAN DIEGO, Jan. 17, 2023 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
Dec 8
2022
Phanes Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate PT199 in combination with Tislelizumab
SAN DIEGO, Dec. 8, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More
Nov 4
2022
PHANES THERAPEUTICS TO PRESENT AT BIOFUTURE™ 2022
Company's CEO to present its innovative oncology pipeline and proprietary bispecific antibody technology platforms SAN DIEGO, Nov. 4, 2022 /PRNewswire/ -- Phanes...
Read More
Oct 14
2022
Phanes Therapeutics announces FDA IND clearance for PT217, an anti-DLL3/anti-CD47 bispecific antibody being developed for patients with small cell lung cancer and other neuroendocrine cancers
SAN DIEGO, Oct. 14, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on oncology, announced today that...
Read More
Aug 23
2022
Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT199 for Advanced Solid Tumors
SAN DIEGO, Aug. 23, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in...
Read More
Aug 2
2022
Phanes Therapeutics’ anti-CD47 antibody patent granted in the US
SAN DIEGO, Aug. 2, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in...
Read More
Jul 1
2022
Phanes Therapeutics’ PT886 granted Orphan Drug Designation for the treatment of pancreatic cancer by the FDA
SAN DIEGO, June 30, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in...
Read More
Jun 21
2022
Phanes Therapeutics’ PT217 receives Orphan Drug Designation for small cell lung cancer from the FDA
SAN DIEGO, June 21, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in...
Read More
